A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
Status:
Withdrawn
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to
evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999
administered twice daily over 14 days. Exploratory measures of PDE2 inhibition will also be
evaluated in blood and blister fluid.